|
Re: iceberg or ice cube?
|
|
Resverlogix Corp.
|
May 17, 2017 10:38PM
|
|
Re: iceberg or ice cube?
|
4
|
Resverlogix Corp.
|
May 17, 2017 02:30PM
|
|
Re: iceberg or ice cube?
|
3
|
Resverlogix Corp.
|
May 17, 2017 02:08PM
|
|
Re: iceberg or ice cube?
|
5
|
Resverlogix Corp.
|
May 17, 2017 01:36PM
|
|
Re: iceberg or ice cube?
|
3
|
Resverlogix Corp.
|
May 17, 2017 11:12AM
|
|
Re: iceberg or ice cube?
|
3
|
Resverlogix Corp.
|
May 17, 2017 10:53AM
|
|
Re: Pfizer enzalutimide perspective
|
|
Zenith Epigenetics
|
May 16, 2017 01:36PM
|
|
Re: Pfizer enzalutimide perspective
|
7
|
Zenith Epigenetics
|
May 16, 2017 03:44AM
|
|
Re: Next News Release
|
2
|
Resverlogix Corp.
|
May 16, 2017 02:33AM
|
|
Re: Next News Release
|
|
Resverlogix Corp.
|
May 16, 2017 02:25AM
|
|
Next News Release
|
5
|
Resverlogix Corp.
|
May 15, 2017 03:02PM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
3
|
Resverlogix Corp.
|
May 12, 2017 01:43PM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
6
|
Resverlogix Corp.
|
May 12, 2017 10:57AM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
5
|
Resverlogix Corp.
|
May 11, 2017 11:50PM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
5
|
Resverlogix Corp.
|
May 11, 2017 04:00PM
|
|
Re: A couple Q2 events for Zenith
|
1
|
Zenith Epigenetics
|
May 10, 2017 12:54PM
|
|
Re: A couple Q2 events for Zenith
|
3
|
Zenith Epigenetics
|
May 10, 2017 12:32PM
|
|
Re: A couple Q2 events for Zenith
|
2
|
Zenith Epigenetics
|
May 10, 2017 10:40AM
|
|
Re: New patent application - USA Inventor
|
5
|
Resverlogix Corp.
|
May 08, 2017 04:45PM
|
|
Re: Analyst Coverage, etc.
|
5
|
Resverlogix Corp.
|
May 07, 2017 07:57PM
|
